Akebia Therapeutics
AKBA
94 hedge funds and large institutions have $210M invested in Akebia Therapeutics in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 33 increasing their positions, 28 reducing their positions, and 6 closing their positions.
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
52.74% more ownership
Funds ownership: 0% → 52.74% (+53%)
50% more call options, than puts
Call options by funds: $1.24M | Put options by funds: $828K
20% more capital invested
Capital invested by funds: $176M → $210M (+$34.5M)
18% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 28
9% more funds holding
Funds holding: 86 → 94 (+8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$4.11M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.73M |
| 3 |
Millennium Management
New York
|
+$2.39M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.69M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$574K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
-$5.74M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$2.71M |
| 3 |
PA
Perceptive Advisors
New York
|
-$2.34M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$974K |
| 5 |
SIM
Spark Investment Management
New York
|
-$469K |
AKBA Hedge Fund Activity: Q4 2016 in Review
94 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q4 2016, worth a combined $210M — up 20% from $176M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new AKBA positions and 6 closed out — a net gain of 8 holders — while 33 added to existing stakes and 28 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $4.11M. The largest seller was First Manhattan, cutting an estimated $5.74M.
- 94 institutional investors held Akebia Therapeutics (AKBA) as of Q4 2016, up from 86 in Q3 2016.
- Funds reported $210M of Akebia Therapeutics stock for Q4 2016, up 20% quarter-over-quarter.
- 14 funds opened new Akebia Therapeutics positions in Q4 2016 and 6 closed out, a net change of +8 holders.
- The largest Akebia Therapeutics buyer in Q4 2016 was Morgan Stanley, an estimated $4.11M added.
- The largest Akebia Therapeutics seller in Q4 2016 was First Manhattan, an estimated $5.74M sold.
Based on aggregated 13F filings for Q4 2016.